Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available. Headquartered in Warsaw, Indiana, USA, Biomet develops, manufactures and markets reconstructive and fixation devices, electrical bone growth stimulators, orthopaedic support devices, operating room supplies, surgical instruments, arthroscopy products, spinal implants, bone cement and substitutes, craniomaxillofacial implants and dental reconstructive implants.

The company maintains over 50 facilities in various countries, including the US, Canada, Europe, Asia-Pacific and Latin America. Biomet conducts the majority of its business in the US, with 62% of its fiscal 2007 revenue coming from customers in the region, 28% from Europe and 10% from other countries.

A current main focus for Biomet is to improve its trauma and spine operations. In these areas, the company has reduced the workforce, made management changes and progressed with computer system implementation, sales support, in-sourcing the manufacture of spinal hardware products and expanding the R&D team, as well as aiming to promote growth through new product development. It has recently undertaken several launches within its fixation product line which should improve this portfolio. In its spinal unit, Biomet is currently developing motion preservation products such as artificial lumber and cervical discs. However, many of the company's competitors are now developing nucleus disc replacement and dynamic stabilisation products which are seen by the industry as improvements on total disc replacement products as they are less-invasive, among other benefits.

While Biomet is currently a publicly-traded company, it is due to be acquired by a private equity consortium for US$46.00 per share in cash, or an equity value of US$11.4 billion. In July 2007, LVB Acquisition LLC and LVB Acquisition Merger Sub Inc successfully completed the tender offer for all outstanding common shares of Biomet.